The Research Network
The Research Network Ltd, founded in 2011, specializes in pharmaceutical R&D, scientific consultancy, project management, outsourcing, training, and due diligence services. The company has in-depth expertise across key drug discovery and development disciplines, working with both small molecules and biotherapeutics. It collaborates with universities and research organizations to advance new drug discovery ventures from lead identification through early clinical development. The company operates a virtual model, building a scientific team of specialists to meet project needs, and has established relationships with CROs across preclinical and clinical disciplines. TRN is also involved in various industry events, conferences, and collaborations, and has a history of successful partnerships and innovations in the pharmaceutical and biotech sectors.
Industries
Nr. of Employees
small (1-50)
The Research Network
Products
Humanised antibody fragment antidote (early-stage project)
Preclinical/early clinical-stage antibody fragment developed as an antidote to anticoagulant-related bleeding events; presented in investor pitch contexts.
Humanised antibody fragment antidote (early-stage project)
Preclinical/early clinical-stage antibody fragment developed as an antidote to anticoagulant-related bleeding events; presented in investor pitch contexts.
Services
Advisory services across discovery and early development for small molecules and biologics.
Program and project leadership including coordination of CROs and external providers for preclinical and clinical activities.
Design and management of ADME/DMPK, in vivo and molecular pharmacology studies to support lead optimisation and candidate selection.
Medicinal chemistry, target validation support and collaborative discovery programs for small molecules and biologics.
A virtual incubator model to enable technology transfer and collaborative drug discovery for emerging projects and spin-outs.
Preparation and delivery of investment pitches, event organisation and engagement with investor audiences to progress projects toward funding.
Advisory services across discovery and early development for small molecules and biologics.
Program and project leadership including coordination of CROs and external providers for preclinical and clinical activities.
Design and management of ADME/DMPK, in vivo and molecular pharmacology studies to support lead optimisation and candidate selection.
Medicinal chemistry, target validation support and collaborative discovery programs for small molecules and biologics.
A virtual incubator model to enable technology transfer and collaborative drug discovery for emerging projects and spin-outs.
Preparation and delivery of investment pitches, event organisation and engagement with investor audiences to progress projects toward funding.
Expertise Areas
- Drug discovery and development
- Medicinal chemistry and synthetic chemistry
- Preclinical ADME/DMPK and in vivo pharmacology
- Biotherapeutics and antibody fragment development
Key Technologies
- ADME/DMPK studies
- In vivo pharmacology models
- Molecular pharmacology assays
- Medicinal chemistry and synthetic chemistry
News & Updates
TRN is no longer accepting new administration network partners but is recruiting for other roles.
TRN operates a virtual model with a team of specialists to meet project needs, working with CROs across disciplines.
TRN is recruiting network partners as consultants in drug discovery and development.
TRN’s CEO attended the ELF chemistry event in Belgium, presenting on 'New Leads for Pain-related Targets via ELF Collaboration.'
TRN representatives attended the RESI Conference in Boston to discuss the new EmstoPA project.
TRN welcomed Christopher North, a Business Administration Apprentice from Middleton Murray.
TRN is no longer accepting new administration network partners but is recruiting for other roles.
TRN operates a virtual model with a team of specialists to meet project needs, working with CROs across disciplines.
TRN is recruiting network partners as consultants in drug discovery and development.
TRN’s CEO attended the ELF chemistry event in Belgium, presenting on 'New Leads for Pain-related Targets via ELF Collaboration.'
TRN representatives attended the RESI Conference in Boston to discuss the new EmstoPA project.
TRN welcomed Christopher North, a Business Administration Apprentice from Middleton Murray.